Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Columbia Labs' Advantage 24 will be studied in United Nations' HIV/STD prevention trial.

This article was originally published in The Tan Sheet

Executive Summary

U.N. STUDY OF ADVANTAGE 24 FOR PREVENTION OF HIV and other sexually transmitted diseases will assess the effectiveness of the nonoxynol-9-containing spermicide for prevention of heterosexual transmission of the diseases, Columbia Labs announced May 14. The company is donating Advantage 24 for use in the project; the study will be funded and conducted by the United Nations Global Program on HIV/AIDS (UNAIDS).

Topics

UsernamePublicRestriction

Register

PS085388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel